Disease Overview：Prostate Cancer（PCa）
Prostate cancer is a malignant neoplasm originating in the prostate gland, predominantly affecting men over 50. Risk factors include advancing age, family history, African ancestry, and certain genetic mutations (e.g., BRCA2). Early-stage disease is often asymptomatic; later presentations may include lower urinary tract symptoms, hematuria, or bone pain due to metastasis—most commonly to axial skeleton and lymph nodes. Diagnosis relies on serum prostate-specific antigen (PSA) testing, digital rectal examination (DRE), multiparametric MRI, and confirmatory transrectal or transperineal ultrasound-guided biopsy. Risk stratification integrates PSA level, Gleason score (now reported as Grade Group 1–5), and clinical stage (TNM classification) to guide management—from active surveillance for low-risk cases to radical prostatectomy, external-beam radiotherapy (including SBRT and IMRT), brachytherapy, or systemic therapies (e.g., androgen deprivation therapy, PARP inhibitors) for advanced disease.
China offers compelling advantages for international patients seeking prostate cancer care. Leading tertiary hospitals—such as Peking University First Hospital, Fudan University Shanghai Cancer Center, and Sun Yat-sen University Cancer Center—house internationally trained urologic oncologists with extensive experience in nerve-sparing robotic-assisted laparoscopic prostatectomy (RALP), high-precision image-guided radiotherapy, and multidisciplinary tumor boards. State-of-the-art infrastructure includes MRI-linear accelerator hybrids, real-time intraoperative ultrasound fusion, and next-generation genomic profiling. Five-year biochemical recurrence-free survival rates for localized disease exceed 90% in high-volume centers, consistent with global benchmarks. Crucially, treatment costs are typically 40–60% lower than in the US or Western Europe—without compromising evidence-based protocols or accreditation standards (JCI- or CNAS-certified facilities).
As a dedicated medical tourism agency, we streamline the international patient journey: verifying physician credentials, coordinating appointments across diagnostics, surgery, and follow-up, providing transparent, all-inclusive pricing (with no hidden fees), arranging visa support, accommodation, and bilingual clinical liaison services—all tailored to individual clinical needs and cultural preferences.
Prostate Cancer: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Prostate Cancer (Urology Department)
Non-Surgical / Conservative / Medication Options
*Indicated for low-risk localized disease, elderly/frail patients, or active surveillance candidates.*
- •Active Surveillance
- *Annual monitoring*: Digital rectal exam ($45), PSA test ($28), multiparametric MRI ($320), repeat targeted biopsy ($850) - *Total annual cost*: $1,243
- •Androgen Deprivation Therapy (ADT)
- *Monthly injections (e.g., goserelin)*: $185–$290 - *LHRH agonist + anti-androgen combo (6 months)*: $2,100–$3,400 - *Baseline labs (testosterone, LFTs, CBC, metabolic panel)*: $110
- •Oral Anti-Androgens (e.g., bicalutamide)
- *Pharmacy dispensing fee*: $12
Surgical / Procedural / Interventional Options
*All procedures performed in Urology Department of Grade 3A hospitals.*
- •Radical Prostatectomy (Robotic/Laparoscopic)
- *Preoperative workup*: PSA ($28), mpMRI ($320), bone scan ($260), ECG + pulmonary function ($135) → $743 total - *Procedure cost*: Robotic ($8,200–$11,500); Laparoscopic ($5,900–$7,800); Open ($4,300–$5,600)
- •External Beam Radiotherapy (EBRT)
- *Simulation + planning CT/MRI*: $480 - *40-fraction IMRT course*: $6,100–$8,900 - *Weekly on-treatment labs (PSA, CBC)*: $220
- •Brachytherapy (Low-Dose Rate)
- *Pre-implant transrectal ultrasound + dosimetry*: $1,250 - *Iodine-125 seed implantation*: $4,700–$6,300
Special / Complex Condition Options
- •Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- *Enzalutamide (12 months)*: $18,600 - *Radium-223 (6 injections)*: $12,800
- •High-Risk Locally Advanced Disease
Quick Selection Guide
- •Age <65, fit, localized disease: Robotic prostatectomy ($9,350 avg) — optimal oncologic control.
- •Age ≥75 or significant comorbidities: Active surveillance ($1,243/yr) or ADT monotherapy ($2,100/6 mo).
- •Budget-constrained (<$5,000): Open prostatectomy ($5,000) or EBRT ($6,100 minimum).
- •High-risk/metastatic: Enzalutamide + ADT — prioritize mCRPC protocols despite higher cost ($18,600/yr).
- •Radiation-intolerant or recurrent post-RT: Salvage cryoablation ($4,800–$6,200) — urology-led, image-guided.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Prostate Cancer Medical Vacation Packages
Curated transparent all-inclusive packages combining Prostate Cancer treatment with China top medical destinations:
